ASX Health July Winners: Sector finally catches a bid to rebound 9pc for month
Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of FebriDX in US subject to CLIA waiver
Clever Culture Systems rose 81.3% in July on news global pharmaceutical giant Novo Nordisk purchased one of its flagship APAS Independence instruments for evaluation
The healthcare sector rose 9.05% in July to be the best of the 11 ASX sectors. A turn up for the books to be sure. While remaining the worst performing sector YTD – up just 1.81% – the S&P ASX Health Care index was in recovery mode in July.
The sector was buoyed by a roughly 13% rise in its biggest name blood products giant CSL (ASX:CSL), which drives much of the index.
Morgans' healthcare analyst Iain Wilkie said there appeared to be a strong sector rotation on the ASX in July.
"During July there certainly was a rotation out of usual strong sectors like financials and more into healthcare and the miners," he told Stockhead.
"Healthcare has been beaten down for quite a long while now and is starting to look attractive.
"I don't think there was anything specific in terms of a catalyst to drive the rotation."
Looking ahead, Wilkie noted the sector may face continued pressure with US President Donald Trump again threatening tariffs " at a very, very, high rate, like 200%" on imported pharmaceuticals.
"Trump has again thrown his weight around but until it actually hits we'll see," Wilkie said.
He said US tariffs shouldn't affect companies like CSL, which is one of the world's largest manufacturers of plasma products.
"Although the US collects over 60% of the world's plasma, it lacks sufficient domestic capacity to process it into finished therapies," he said.
"As a result, imported plasma products are critical to meeting national demand.
"Introducing tariffs on these products would likely be counterproductive as they wouldn't foster viable domestic alternatives and could drive up costs, potentially limiting patient access and causing harm."
How ASX biotechs performed in July
CODE COMPANY PRICE 1 MONTH RETURN % MARKET CAP
PAB Patrys Limited $ 0.002 181.8% 6.9
LDX Lumos Diagnostics $ 0.073 170.4% 55.4
NSB Neuroscientific $ 0.235 170.1% 79.8
NXS Next Science Limited $ 0.140 109.0% 41.7
NOX Noxopharm Limited $ 0.110 103.7% 30.7
CMB Cambium Bio Limited $ 0.425 102.4% 8.2
DVL Dorsavi Ltd $ 0.028 86.7% 27.3
ICR Intelicare Holdings $ 0.013 85.7% 6.3
CC5 Clever Culture $ 0.029 81.3% 56.9
EMD Emyria Limited $ 0.049 75.0% 28.1
CU6 Clarity Pharma $ 4.370 74.8% 1,471.5
HMD Heramed Limited $ 0.012 71.4% 10.5
MX1 Micro-X Limited $ 0.083 69.4% 54.0
TTX Tetratherix Limited $ 5.020 66.2% 131.7
CAN Cann Group Ltd $ 0.016 60.0% 9.8
NYR Nyrada Inc. $ 0.370 54.2% 77.8
VBS Vectus Biosystems $ 0.06 50.0% 3.2
CSX Cleanspace Holdings $ 0.760 46.2% 59.5
MSB Mesoblast Limited $ 2.380 43.8% 3,046.3
AVE Avecho Biotech Ltd $ 0.005 42.9% 15.9
HIQ Hitiq Limited $ 0.020 42.9% 9.9
AYA Artryalimited $ 1.025 42.4% 116.7
ANR Anatara Ls Ltd $ 0.007 40.0% 1.5
ATH Alterity Therap Ltd $ 0.014 40.0% 128.9
CBL Control Bionics $ 0.040 37.9% 12.1
EYE Nova EYE Medical Ltd $ 0.150 36.4% 41.2
IBX Imagion Biosys Ltd $ 0.015 36.4% 3.0
IPD Impedimed Limited $ 0.047 34.3% 93.4
RCE Recce Pharmaceutical $ 0.388 33.6% 108.4
NTI Neurotech Intl $ 0.020 33.3% 21.0
VFX Visionflex Group Ltd $ 0.00 33.3% 6.7
AT1 Atomo Diagnostics $ 0.018 28.6% 14.2
AHC Austco Healthcare $ 0.370 27.6% 137.0
TRP Tissue Repair $ 0.240 26.3% 14.5
SOM SomnoMed Limited $ 0.815 25.4% 171.8
1AD Adalta Limited $ 0.003 25.0% 2.8
ADR Adherium Ltd $ 0.005 25.0% 9.0
BIT Biotron Limited $ 0.003 25.0% 3.3
CUV Clinuvel Pharmaceut. $ 12.970 25.0% 617.5
FRE Firebrickpharma $ 0.077 24.2% 17.5
CMP Compumedics Limited $ 0.315 23.5% 66.3
NEU Neuren Pharmaceut. $ 17.290 22.5% 2,150.6
ILA Island Pharma $ 0.170 21.4% 40.8
ATX Amplia Therapeutics $ 0.240 20.0% 111.9
DOC Doctor Care Anywhere $ 0.125 19.0% 47.7
EBR EBR Systems $ 1.410 18.0% 514.6
LTP Ltr Pharma Limited $ 0.340 17.2% 60.6
PAR Paradigm Bio. $ 0.355 16.4% 136.1
LGP Little Green Pharma $ 0.115 16.2% 35.1
M7T Mach7 Tech Limited $ 0.380 15.2% 89.3
ALC Alcidion Group Ltd $ 0.115 15.0% 154.4
NC6 Nanollose Limited $ 0.077 14.9% 24.1
CYC Cyclopharm Limited $ 1.040 14.3% 113.4
SPL Starpharma Holdings $ 0.100 13.6% 43.9
MVF Monash IVF Group Ltd $ 0.800 13.5% 309.8
SNT Syntara Limited $ 0.060 13.2% 97.6
CSL CSL Limited $ 270.900 13.1% 128,514.7
PME Pro Medicus Limited $ 321.890 12.9% 33,058.3
CVB Curvebeam Ai Limited $ 0.080 12.7% 33.2
IMM Immutep Ltd $ 0.270 12.5% 385.3
MVP Medical Developments $ 0.610 11.9% 64.8
TRJ Trajan Group Holding $ 0.800 11.9% 121.9
GLH Global Health Ltd $ 0.076 11.8% 4.5
VIT Vitura Health Ltd $ 0.07 11.3% 47.0
PIQ Proteomics Int Lab $ 0.360 10.8% 57.3
IRX Inhalerx Limited $ 0.042 10.5% 9.0
IDT IDT Australia Ltd $ 0.098 10.1% 40.7
NUZ Neurizon Therapeutic $ 0.170 9.7% 81.2
PGC Paragon Care Limited $ 0.400 9.6% 653.8
RHY Rhythm Biosciences $ 0.059 9.3% 17.4
1AI Algorae Pharma $ 0.006 9.1% 10.1
CTQ Careteq Limited $ 0.012 9.1% 2.8
AHX Apiam Animal Health $ 0.565 8.7% 103.0
ARX Aroa Biosurgery $ 0.630 8.6% 224.3
OCC Orthocell Limited $ 1.275 8.5% 309.7
MAP Microbalifesciences $ 0.092 8.2% 47.4
PSQ Pacific Smiles Grp $ 1.670 8.1% 269.9
PNV Polynovo Limited $ 1.290 7.9% 858.4
RMD ResMed Inc. $ 42.450 7.9% 61,930.3
PTX Prescient Ltd $ 0.047 6.8% 38.7
REG Regis Healthcare Ltd $ 8.370 6.8% 2,545.6
TYP Tryptamine Ltd $ 0.03 6.7% 44.6
SDI SDI Limited $ 0.883 6.3% 104.6
COH Cochlear Limited $ 318.520 6.0% 20,541.2
RHC Ramsay Health Care $ 38.770 5.7% 8,808.5
IDX Integral Diagnostics $ 2.670 5.1% 1,001.8
IMC Immuron Limited $ 0.064 4.9% 16.9
OCA Oceania Healthc Ltd $ 0.660 4.8% 461.5
EBO Ebos Group Ltd $ 37.250 4.7% 7,552.6
RAD Radiopharm $ 0.023 4.5% 54.4
ACW Actinogen Medical $ 0.024 4.3% 76.3
IIQ Inoviq Ltd $ 0.385 4.1% 43.5
AGH Althea Group $ 0.026 4.0% 21.4
IME Imexhs Limited $ 0.300 3.4% 15.8
CYP Cynata Therapeutics $ 0.155 3.3% 37.3
SHL Sonic Healthcare $ 27.610 3.1% 13,532.2
FPH Fisher & Paykel H. $ 34.090 1.4% 19,481.0
CTE Cryosite Limited $ 0.750 0.7% 36.6
VLS Vita Life Sciences.. $ 2.26 0.4% 124.4
ACR Acrux Limited $ 0.016 0.0% 7.0
BP8 Bph Global Ltd $ 0.002 0.0% 2.1
EMV Emvision Medical $ 1.740 0.0% 150.1
EOF Ecofibre Limited $ 0.020 0.0% 7.6
EPN Epsilon Healthcare $ 0.024 0.0% 7.2
NAN Nanosonics Limited $ 4.050 0.0% 1,196.3
OSX Osteopore Limited $ 0.011 0.0% 2.6
TD1 Tali Digital Limited $ 0.001 0.0% 4.2
TRI Trivarx Ltd $ 0.008 0.0% 5.0
TRU Truscreen $ 0.016 0.0% 12.3
ACL Au Clinical Labs $ 2.760 -0.7% 536.1
CGS Cogstate Ltd $ 1.730 -0.9% 292.9
MYX Mayne Pharma Ltd $ 4.950 -1.0% 405.4
ANN Ansell Limited $ 29.950 -1.1% 4,410.5
AFP Aft Pharmaceuticals $ 2.400 -1.2% 259.6
RGT Argent Biopharma Ltd $ 0.080 -1.2% 4.7
RAC Race Oncology Ltd $ 1.160 -1.3% 198.9
SNZ Summerset Grp Hldgs $ 10.300 -1.3% 2,513.8
HLS Healius $ 0.770 -1.9% 548.2
ALA Arovella Therapeutic $ 0.098 -2.0% 117.7
BMT Beamtree Holdings $ 0.245 -2.0% 72.6
ONE Oneview Healthcare $ 0.245 -2.0% 185.7
4DX 4Dmedical Limited $ 0.235 -2.1% 136.2
COV Cleo Diagnostics $ 0.380 -2.6% 48.8
RHT Resonance Health $ 0.038 -2.6% 17.5
AVH Avita Medical $ 1.670 -2.6% 217.6
SIG Sigma Health Ltd $ 2.890 -3.3% 32,726.4
PYC PYC Therapeutics $ 1.240 -4.2% 729.1
IXC Invex Ther $ 0.085 -4.5% 6.9
OIL Optiscan Imaging $ 0.105 -4.5% 87.7
ZLD Zelira Therapeutics $ 0.41 -6.8% 4.9
MDR Medadvisor Limited $ 0.075 -7.4% 43.8
BDX Bcaldiagnostics $ 0.058 -7.9% 20.5
GSS Genetic Signatures $ 0.330 -9.6% 76.1
CDX Cardiex Limited $ 0.036 -10.0% 18.7
PER Percheron $ 0.009 -10.0% 10.9
AGN Argenica $ 0.680 -10.5% 86.1
OSL Oncosil Medical $ 1.070 -10.8% 20.2
ECS ECS Botanics Holding $ 0.008 -11.1% 11.0
PEB Pacific Edge $ 0.085 -11.5% 75.9
IVX Invion Ltd $ 0.096 -12.7% 8.2
EZZ EZZ Life Science $ 2.030 -13.2% 99.1
TLX Telix Pharmaceutical $ 21.050 -13.8% 6,991.3
AVR Anteris Technologies $ 5.130 -16.4% 179.8
DXB Dimerix Ltd $ 0.470 -18.3% 285.1
SHG Singular Health $ 0.300 -18.9% 93.5
IMR Imricor Med Sys $ 1.225 -19.4% 324.2
MEM Memphasys Ltd $ 0.004 -20.0% 7.9
PCK Painchek Ltd $ 0.035 -22.2% 66.3
CHM Chimeric Therapeutic $ 0.003 -25.0% 11.4
VHL Vitasora Health Ltd $ 0.03 -28.2% 46.4
UCM Uscom Limited $ 0.01 -31.3% 2.9
UBI Universal Biosensors $ 0.02 -31.4% 7.2
IMU Imugene Limited $ 0.270 -38.9% 77.2
BOT Botanix Pharma Ltd $ 0.150 -53.1% 289.3
Patrys (ASX:PAB) rose ~182% in July after announcing a solid June quarter including a board restructure, $300,000 capital raise and actively pursuing partnering and licensing opportunities for both of its oncological cell therapy deoxymab assets.
In July Patrys also announced a fully underwritten, pro-rata non-renounceable entitlement offer of three fully paid ordinary shares for every four shares held at an issue price of $0.001 per Share, together with on free-attaching new share for every four shares applied for and issued, to raise up to ~$1.78m.
Lumos Diagnostics (ASX:LDX) rose more than 170% in July after l anding a landmark six-year distributor deal worth hundreds of millions of dollars to sell its rapid point-of-care diagnostic FebriDx in the US market.
The FebriDx product is a simple test able to differentiate between bacterial and non-bacterial acute respiratory infections. The lucrative US licensing deal with Hong-Kong based PHASE Scientific could see Lumos net up to to US$317m (~A$487m), and has been described as one of the largest distribution deals of its type to be done by an ASX-listed point-of-care diagnostics company.
Adelaide-based Clever Culture Systems (ASX:CC5), rose 81.3% in July after announcing global pharmaceutical giant Novo Nordisk had purchased one of its flagship APAS Independence instruments for evaluation.
The machine will be delivered to Novo's central team in Denmark, where it will undergo a full-scale evaluation to assess its suitability for deployment across Novo's global manufacturing network.
The APAS Independence uses AI technology to automate one of the most time-consuming parts of microbiology, analysing agar plates for contamination.
Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) was up 74.8% in July after completing a large $203m institutional placement at a 15% premium to the company's 15-day average price, to fund their clinical program.
Executive chairman Dr Alan Taylor told Stockhead the 'fast, well executed and sizeable' placement was to a small group of local institutional investors "close to the company".
'I have never done a deal that fast,' Taylor said.
'A week ago, I would have said we were not doing a capital raising, but there was a lot of interest from a very concentrated group .'
At Stockhead, we tell it like it is. While Lumos Diagnostics and Clever Culture Systems are Stockhead advertisers, the companies did not sponsor this article.
The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
10 minutes ago
- ABC News
Brandy production returns to Coonawarra as winery revives distilling heritage
For the first time in decades, brandy is returning to the Coonawarra. The region was once a major producer of the wine-based liquor, before it dropped out of fashion. The idea to bring back brandy to the Coonawarra came from the director of Majella Wines, Brian "Prof" Lynn. After contemplating launching a spirit, he thought brandy would be the most natural progression from wine. It has so far been a straightforward addition for the business, requiring only a distillation still in addition to their existing wine, rainwater and wooden ageing barrels. Mr Lynn has found the distilling process to be quick, only taking about six hours. But the ageing process is slow, with all brandy legally required to be aged for two years in a wooden cask. Despite the strong historic origins of brandy in the region, Majella's release is the first to include the region on the labelling. In the early 1900s, tastes were changing and demand for dry reds dwindled. The brandy produced with the surplus grapes would eventually become generically branded brandy. But as other wine varieties grew in popularity, Coonawarra's brandy production declined and eventually stopped in the late 20th century. Much of the knowledge about Coonawarra brandy has been lost through the decades, but there are some in the region still with connections to the liquor. Coonawarra resident Diana Clayfield's father, Arthur Hoffmann, was a viticulturalist, wine and brandy maker in the region. "He enjoyed doing it [making brandy]," she said. Ms Clayfield remembers the generation before her enjoying a brandy, and sometimes even using it for medicinal purposes. "If you had a flu, they warmed brandy and wine up together and had it as a medicine," she said. It was this connection with medicine that helped brandy to become so popular, with production peaking in the 1960s. Luke McCarthy has extensively researched and written about Australian spirits and brandy. He said hospital brandy emerged around the turn of the 20th century, with major brands producing it into the 1940s. The term fell out of vogue around the same time brandy production declined. Another blow was the federal excise on brandy, facing a large increase in the 1970s to be closer to other spirits. "It's a combination of economic forces, government intervention and then shifting consumer trends, which have seen brandy really ride this sort of roller coaster ride over the last 100 years," Mr McCarthy said. Australian Distillers Association president Holly Klintworth said, although the market for other spirits like gin had become crowded, there was an opportunity ahead for brandy. "There's definitely a place in Australia for brandy and I hope that it's only a matter of time before more and more people start to rediscover just how amazing brandy can be," she said. And it could be a money spinner for wineries — Ms Klintworth's distillery turns "about $16,000 worth of wine into the equivalent of $1.5 million worth of brandy". "It makes a lot of sense. We've got so many wine regions," she said. Mr Lynn agrees that conditions are right for a comeback. He was already ageing a fresh batch of brandy to release in future years. "In the old days, brandy was huge; everyone drank brandy," he said.
News.com.au
10 minutes ago
- News.com.au
SuperCoach NFL is here and it changes the fantasy game
The NFL is the biggest sporting juggernaut on the planet and now it has a fantasy platform to match, with the launch of SuperCoach NFL. In a major expansion of the SuperCoach universe, Australia's most-loved fantasy game is heading stateside, combining all the stats, features and formats fans love with the fast-paced world of American football. Whether you're a seasoned fantasy coach or new to the game, SuperCoach NFL gives you the tools and flexibility to play your way. Why SuperCoach NFL? SuperCoach NFL offers both Classic and Draft formats in one game. That means you can build a squad within a salary cap or draft live against your mates. No matter how you want to play, there's a format for you. Add to that live scoring, weekly price changes, flexible team structures plus the powerful SuperCoach experience and you've got a game that rewards strategy, knowledge and instinct. And it's free to play. Two elite ways to showcase your coaching Classic: Select your team under a $279.2m salary cap, make trades each week and ride the ups and downs of form, injury and match-ups across the NFL season. Draft: Go head-to-head with mates in a live draft. No duplicate players, no excuses. Build combos, manage byes and dominate your league. There's also the NFL Cup and tipping to test your knowledge of everything NFL. Built for fans, new and diehard SuperCoach NFL is designed to make the game accessible for everyone from the NFL-obsessed to beginners. A built-in Beginner's Guide breaks down everything you need to know, including setting up a team, creating a league, running a draft, game scoring and player trading. Visit the Help & Info section. Plus, expert content, team reveals and cheat sheets published on SuperCoach web and app -and CODE Sports – will help you make smarter calls every week of the season. Make every play count From superstar quarterbacks to breakout wide receivers, SuperCoach NFL captures the moments that matter. Track form, price changes and match-ups in real-time. Adjust your tactics, chase value, or stack combos like Patrick Mahomes to Travis Kelce. Every decision shapes your path to fantasy glory. SuperCoach Plus gives you the edge Already a SuperCoach Plus subscriber? You're in luck. Unlock exclusive SuperCoach NFL features like projected player scores, advanced stats, Draft rankings and trade recommendations, all built to help you outsmart your mates. If not subscribed, follow the SuperCoach Plus links on the SuperCoach app of web. Get in the game The NFL season kicks off September 5. Start building your Classic squad today or begin planning your big Draft night with mates. Create your league, start scouting players and prepare for a fantasy season like no other.
News.com.au
10 minutes ago
- News.com.au
Shock as Aus big bank increases interest rates
One of Australia's big four banks has quietly increased its home loan interest rates in a shock move, going against the grain just as another Big Four bank dropped theirs. ANZ's digital bank – ANZ Plus – which began offering home loans almost two years ago – emerged Thursday morning with a 0.16 percentage point rise in interest rates on comparison site Canstar's database. It showed the same hike for both residential and investments variable home loan interest rates on ANZ Plus, showing an increase from 5.59 per cent to 5.75 per cent per annum variable rate for new owner-occupier loans and up from 5.89pp to 6.05 per cent variable for investment properties. This as National Australia Bank was flagged to have put in a 0.25pp cut in tailored investment home loans fixed for one to two years, and a 0.1 per cent fall for those fixed for three and more years; as well as a residential fixed home loan rate cut of 0.1 points for interest only and 0.25pp for principal and interest. The surprise contrast has raised concern given ANZ Plus' shift into home loans in 2023 was touted by former ANZ CEO Shayne Elliot as the bank's future dominant distribution channel for home loans. No official statement on the move has been made by ANZ, but it did issue a media release over a series of changes to its home loan policies to make it easier for self-employed Aussies to qualify for home loans, including changes to the 3 per cent interest buffer used in calculations. The Reserve Bank is widely expected to cut the official cash rate at its Tuesday monetary policy meeting, and has already cut interest rates twice in 2025, dropping from 4.35pc to 3.85pc.
